Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable. A retrospective study by the Chronic Malignancies Working Party of the EBMT / Mclornan, Donal P; Malpassuti, Vittoria; Lippinkhof-Kozijn, Anne; Potter, Victoria; Beelen, Dietrich; Bunjes, Donald; Sengeloev, Henrik; Radujkovic, Aleksandar; Passweg, Jakob; Chalandon, Yves; Kröger, Nicolaus; Wulf, Gerald G; Johansson, Jan-Erik; Ciceri, Fabio; Bornhäuser, Martin; Holler, Ernst; Guffroy, Blandine; Martin, Sonja; Neubauer, Andreas; Gramatski, Martin; Robin, Marie; Iacobelli, Simona; Hayden, Patrick; Hernández Boluda, Juan C; Czerw, Tomasz; Yakoub-Agha, Ibrahim. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 190:3(2020), pp. 437-441. [10.1111/bjh.16537]
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable. A retrospective study by the Chronic Malignancies Working Party of the EBMT
Iacobelli, Simona;
2020
Abstract
Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.File | Dimensione | Formato | |
---|---|---|---|
McLornan_Outcome-allogeneic_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
200.42 kB
Formato
Adobe PDF
|
200.42 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.